The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks ...

We recently published a list of 8 Best Low Volatility Stocks To Buy Right Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best low ...

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...